Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukaemia
Thomas O’Hare,1,2 Christopher A. Eide,2 and Michael W. N. Deininger2 1Howard Hughes Medical Institute, Chevy Chase, MD; 2Oregon Health & Science University Cancer Institute, Portland, OR
Mutations in the kinase domain (KD) of BCR-ABL are the most prevalent mechanism of acquired imatinib resistance in patients with chronic myeloid leukaemia (CML).
see attachment for full PDF of above article